Beam Therapeutics (NasdaqGS:BEAM) Earnings Call Presentation

BEAM-302 Topline Data Update March 25, 2026 NASDAQ: BEAM 2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding: the therapeutic applications and potential of our technology, including with respect to AATD; our plans, and anticipated timing, to advance our programs, including risto-cel, BEAM-103, BEAM-301, BEAM-304 and ...